Related Experiment Videos
DNA hypo-methylating agents and sickle cell disease.
Yogen Saunthararajah1, Donald Lavelle, Joseph DeSimone
1University of Illinois at Chicago, 900 S Ashland Avenue, Chicago, IL 60607-7173, USA. yogen@uic.edu
British Journal of Haematology
|August 26, 2004
Summary
Pharmacologic reactivation of fetal haemoglobin (HbF) using DNA hypomethylation agents like decitabine shows promise for treating sickle cell disease (SSD). Further research is needed to confirm long-term safety and effectiveness.
Area of Science:
- Hematology
- Molecular Biology
- Pharmacology
Background:
- High fetal haemoglobin (HbF) levels reduce sickle haemoglobin (HbS) polymerization, decreasing morbidity and mortality in sickle cell disease (SSD).
- HbF gene silencing is linked to DNA methylation.
- Pharmacologic HbF reactivation is a therapeutic target for SSD.
Purpose of the Study:
- To evaluate DNA hypomethylation agents for reactivating HbF in SSD.
- To address safety concerns and clarify the mechanism of action for HbF reactivation.
Main Methods:
- Investigated cytosine analogues, 5-azacytidine and decitabine, as DNA hypomethylating agents.
- Reviewed clinical trial data and preclinical studies on decitabine's efficacy and safety.
- Examined the role of DNA methyl-transferase inhibition in HbF gene expression.
Main Results:
- 5-azacytidine and decitabine demonstrated significant efficacy in HbF reactivation.
- Concerns about 5-azacytidine's carcinogenicity have delayed its development.
- Decitabine's mechanism of action confirmed as DNA hypomethylation, tempering safety concerns.
Conclusions:
- Pharmacologic HbF reactivation via DNA hypomethylation is a promising disease-modifying strategy for SSD.
- Decitabine shows potential for chronic use in SSD management.
- Larger studies are necessary to validate the long-term safety and effectiveness of this approach.